Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.
Mahesh Swaminathan, MBBS
Articles by Mahesh Swaminathan, MBBS